Single application head lice product capable of killing both eggs and lice.

Dr Cherrell Hirst


Cherrell has had a distinguished clinical career in the detection and diagnosis of breast cancer. She is CEO and deputy chair of lifesciences venture capital fund QIC BioVentures, chair of Impedimed, and a non Executive Director of Tissue Therapies, Relevare and Xenome. She served as a member of the AusIndustry IR&D Board of Biologics Committee from 2001 -2006.

Dr Hirst has held non-executive directorships in financial services companies including Suncorp and MBF and is currently a Director of Medibank Private and the Avant Mutual Group.  Dr Hirst was Chancellor of QUT from 1994-2004 and was elected to the Academy of Technology Sciences and Engineering in 2008. She has received three honorary doctorates, the award of Officer of the Order of Australia and a centenary medal in recognition of her work in breast cancer and education. Dr Hirst was Queenslander of the Year in 1995.

Latest News

Oct 21, 2014 Hatchtech Announces Successful Results from Phase 2 Ovicidal Study

Sep 02, 2014 Hatchtech Announces Successful Phase 3 Results

Dec 11, 2013 Hatchtech Receives SPA and Announces Patent Grants

Oct 31, 2013 Hatchtech Completes $12.6m Capital Raise, Secures Funds for Phase III and NDA Submission